Table 3 Luteolin increased the sensitivity of xenograft model of ovarian cancer to cisplatin. The Q value was calculated to evaluate the effect of the combination of the two drugs. The inhibition rate in each group was measured by tumor weight reduction compared to the control group. CDDP combined with luteolin (40 mg) showed a synergistic inhibitory effect on the growth of xenograft tumor (Q = 1.16 ± 0.03, > 1, P < 0.01). The data were expressed as the mean ± S.D. in triplicate
Drugs | Inhibition rate (%) | Q value |
|---|---|---|
Luteolin (40 mg) | 39 ± 1.64 | |
Luteolin (20 mg) | 34.4 ± 1.89 | |
Luteolin (10 mg) | 21.3 ± 6.83 | |
CDDP (3 mg) | 48.6 ± 1.55 | |
Luteolin (40 mg) + CDDP (3 mg) | 79.8 ± 3.5 | 1.16 ± 0.03 |
Luteolin (20 mg) + CDDP (3 mg) | 62.8 ± 3.09 | 0.95 ± 0.03 |
Luteolin (10 mg) + CDDP (3 mg) | 55.7 ± 1.64 | 0.94 ± 0.05 |